Hormonal
The endogenous circadian pacemaker significantly modulates sleep propensity, with sleep latency being shortest (highest propensity) when sleep coincides with the minimum of the core body temperature rhythm, and longest (lowest propensity) when it coincides with the maximum.
To fall asleep faster, try to align your bedtime with your body's natural temperature minimum, which typically occurs in the early morning hours (e.g., 4-6 AM) for most people. If you must sleep at other times, expect longer sleep latency. Consistent sleep-wake times help stabilize this rhythm.
Sleep latency varied significantly with the phase of the endogenous circadian rhythm (Fig. 2E). Minimum latencies were observed in the interval 165°-195°. Maximum latencies were observed at the minimum component of the temperature rhythm, which corresponded to the interval between 22:00 hr and 06:00 hr.
Why this rating
High-quality experimental design using forced desynchrony protocol in healthy humans, allowing separation of circadian and homeostatic components.
Source
Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans
Derk‐Jan Dijk et al. · Journal of Neuroscience · 1995
DOI 10.1523/jneurosci.15-05-03526.1995
More from this paper
- Total sleep time and sleep efficiency are significantly modulated by the circadian phase, being highest when the scheduled sleep episode coincides with the falling and plateau phases of the core body temperature rhythm, and lowest when it coincides with the rising phase.Strong
- The circadian pacemaker significantly modulates the amount of REM sleep, with maximum REM sleep occurring shortly after the minimum of the core body temperature rhythm, and minimum REM sleep occurring during the plateau phase.Strong
- Slow-wave activity (SWA, 0.75-4.5 Hz) in non-REM sleep is modulated by both the circadian pacemaker and the homeostatic sleep process, with the circadian modulation peaking around the minimum of the core body temperature rhythm.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →